172 related articles for article (PubMed ID: 21494127)
1. Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease.
Suzuki T; Nozawa T; Fujii N; Sobajima M; Ohori T; Shida T; Matsuki A; Kameyama T; Inoue H
Coron Artery Dis; 2011 Aug; 22(5):352-8. PubMed ID: 21494127
[TBL] [Abstract][Full Text] [Related]
2. Plaque regression in one artery is not necessarily associated with parallel changes in other vascular beds.
Suzuki T; Nozawa T; Fujii N; Sobajima M; Ohori T; Shida T; Matsuki A; Kameyama T; Inoue H
Heart Vessels; 2011 May; 26(3):242-51. PubMed ID: 20953613
[TBL] [Abstract][Full Text] [Related]
3. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
4. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ
Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein levels and outcomes after statin therapy.
Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
[TBL] [Abstract][Full Text] [Related]
6. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
7. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.
Shukla A; Sharma MK; Jain A; Goel PK
Indian Heart J; 2005; 57(6):675-80. PubMed ID: 16521637
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia.
Ercan E; Tengiz I; Altuglu I; Sekuri C; Aliyev E; Ercan HE; Akin M
Kardiol Pol; 2004 May; 60(5):454-8. PubMed ID: 15247960
[TBL] [Abstract][Full Text] [Related]
9. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
Sang ZC; Wang F; Zhou Q; Li YH; Li YG; Wang HP; Chen SY
Chin Med J (Engl); 2009 Jul; 122(14):1615-20. PubMed ID: 19719960
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent.
Azar M; Valentin E; Badaoui G; Kassab R; Sarkis A; Azar RR
Am J Cardiol; 2011 Jun; 107(11):1571-4. PubMed ID: 21439529
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
12. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
13. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
[TBL] [Abstract][Full Text] [Related]
14. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
[TBL] [Abstract][Full Text] [Related]
15. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels.
Takahashi Y; Satoh M; Minami Y; Tabuchi T; Itoh T; Nakamura M
Clin Sci (Lond); 2010 Jul; 119(9):395-405. PubMed ID: 20524934
[TBL] [Abstract][Full Text] [Related]
16. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.
Komukai K; Kubo T; Kitabata H; Matsuo Y; Ozaki Y; Takarada S; Okumoto Y; Shiono Y; Orii M; Shimamura K; Ueno S; Yamano T; Tanimoto T; Ino Y; Yamaguchi T; Kumiko H; Tanaka A; Imanishi T; Akagi H; Akasaka T
J Am Coll Cardiol; 2014 Dec; 64(21):2207-17. PubMed ID: 25456755
[TBL] [Abstract][Full Text] [Related]
17. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy.
Puri R; Nissen SE; Shao M; Uno K; Kataoka Y; Kapadia SR; Tuzcu EM; Nicholls SJ
Am J Cardiol; 2014 Nov; 114(10):1465-72. PubMed ID: 25282317
[TBL] [Abstract][Full Text] [Related]
18. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
19. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study.
Ostad MA; Eggeling S; Tschentscher P; Schwedhelm E; Böger R; Wenzel P; Meinertz T; Munzel T; Warnholtz A
Atherosclerosis; 2009 Jul; 205(1):227-32. PubMed ID: 19150064
[TBL] [Abstract][Full Text] [Related]
20. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
